Browse > Article

Diagnostic Performance of Whole-Body Diffusion-Weighted Imaging Compared to PET-CT Plus Brain MRI in Staging Clinically Resectable Lung Cancer  

Usuda, Katsuo (Department of Thoracic Surgery, Kanazawa Medical University)
Sagawa, Motoyasu (Department of Thoracic Surgery, Kanazawa Medical University)
Maeda, Sumiko (Department of Thoracic Surgery, Kanazawa Medical University)
Motono, Nozomu (Department of Thoracic Surgery, Kanazawa Medical University)
Tanaka, Makoto (Department of Thoracic Surgery, Kanazawa Medical University)
Machida, Yuichiro (Department of Thoracic Surgery, Kanazawa Medical University)
Matoba, Takuma Matsui Munetaka (Department of Radiology, Kanazawa Medical University)
Watanabe, Naoto (Department of Radiology, Kanazawa Medical University)
Tonami, Hisao (Department of Radiology, Kanazawa Medical University)
Ueda, Yoshimichi (Department of Pathophysiological and Experimental Pathology, Kanazawa Medical University)
Uramoto, Hidetaka (Department of Thoracic Surgery, Kanazawa Medical University)
Publication Information
Asian Pacific Journal of Cancer Prevention / v.17, no.6, 2016 , pp. 2775-2780 More about this Journal
Abstract
Background: Precise staging of lung cancer is usually evaluated by PET-CT and brain MRI. Recently, however, whole-body diffusion-weighted magnetic resonance imaging (WB-DWI) has be applied. The aim of this study is to determine whether the diagnostic performance of lung cancer staging by WB-DWI is superior to that of PET-CT+brain MRI. Materials and Methods: PET-CT + brain MRI and WB-DWI were used for lung cancer staging before surgery with 59 adenocarcinomas, 16 squamous cell carcinomas and 6 other carcinomas. Results: PET-CT + brain MRI correctly identified the pathologic N staging in 67 patients (82.7%), with overstaging in 5 (6.2%) and understaging in 9 (11.1%), giving a staging accuracy of 0.827. WB-DWI correctly identified the pathologic N staging in 72 patients (88.9%), with overstaging in 1 (1.2%) and understaging in 8 patients (9.9%), giving a staging accuracy of 0.889. There were no significant differences in accuracies. PET-CT + brain MRI correctly identified the pathologic stages in 56 patients (69.1%), with overstaging in 7 (8.6%) and understaging in 18 (22.2%), giving a staging accuracy of 0.691. WB-DWI correctly identified the pathologic stages in 61 patients (75.3%), with overstaging in 4 (4.9%) and understagings in16(19.7%), giving a staging accuracy of 0.753. There were no significant difference in accuracies. Conclusions: Diagnostic efficacy of WB-DWI for lung cancer staging is equivalent to that of PET-CT + brain MRI.
Keywords
Lung cancer; staging; whole body diffusion-weighted magnetic resonance imaging; MRI; PET-CT;
Citations & Related Records
Times Cited By KSCI : 2  (Citation Analysis)
연도 인용수 순위
1 Kim HS, Lee KS, Ohno Y, et al (2015). PET/CT versus MRI for diagnosis, staging, and follow-up of lung cancer. J Magn Reson Imaging, 42, 247-60.   DOI
2 Sommer G, Wiese M, Winter L, et al (2012). Preoperative staging of non-small-cell lung cancer: comparison of wholebody diffusion-weighted magnetic resonance imaging and 18F-fluorodeoxyglucose-positron emission tomography/computed tomography. Eur Radiol, 22, 2859-67.   DOI
3 Konishi J, Yamazaki K, Tsukamoto E, et al (2003). Mediastinal lymph node staging by FDG-PET in patients with nonsmall cell lung cancer: analysis of false-positive FDG-PET findings. Respirat, 70, 500-6.   DOI
4 Kosucu P, Tekinbas C, Erol M, et al (2009). Mediastinal lymph nodes. Assessment with diffusion-weighted MR imaging. J Magn Reson Imaging, 30, 292-7.   DOI
5 Kwee TC, Takahara T, Ochiai R, et al (2009). Whole-body diffusion-weighted magnetic resonance imaging. Eur J Radiol, 70, 409-17.   DOI
6 Lambregts DMJ, Maas M, Cappendijk VC, et al (2011). Wholebody diffusion-weighted magnetic resonance imaging: current evidence in oncology and potential role in colorectal cancer staging. Eur J Cancer, 47, 2107-16.   DOI
7 Laurent V, Trausch G, Bruot O, et al (2010). Comparative study of two whole-body imaging techniques in the case of melanoma metastases: advantages of multi-contrast MRI examination including a diffusion-weighted sequence in comparison with PET-CT. Eur J Radiol, 75, 376-83.   DOI
8 Le Bihan D, Breton E, Lallemand D, et al (1988). Separation of diffusion and perfusion in intravoxel incoherent motion MR imaging. Radiol, 168, 497-505.   DOI
9 Takano A, Oriuchi N, Tsushima Y, et al (2008). Detection of metastatic lesions from malignant pheochromocytoma and paraganglioma with diffusion-weighted magnetic resonance imaging: comparison with $^{18}F$-FDG positron emission tomography and $^{123}I$-MIBG scintigraphy. Ann Nucl Med, 22 , 395-401.   DOI
10 Stecco A, Romano G, Negru M, et al (2009). Whole-body diffusion-weighted magnetic resonance imaging in the staging of oncological patients: comparison with positron emission tomography computed tomography (PET-CT) in a pilot study. Radiol Med, 114, 1-17.   DOI
11 Takenaka D, Ohno Y, Matsumoto K, et al (2009). Detection of bone metastases in non-small cell lung cancer patients: comparison of whole-body diffusion-weighted imaging (DWI), whole-body MR imaging without and with DWI, whole-body FDG-PET/CT, and bone scintigraphy. J Magn Reson Imaging, 30, 298-308.   DOI
12 Usuda K, Maeda S, Motono N, et al (2015). Diagnostic Performance of Diffusion-Weighted Imaging for Multiple Hilar and Mediastinal Lymph Nodes with FDG Accumulation. Asian Pac J Cancer Prev, 16, 6401-6   DOI
13 Usuda K, Sagawa M, Motono N, et al (2014). Diagnostic performance of diffusion weighted imaging of malignant and benign pulmonary nodules and masses. Comparison with positron emission tomography. Asian Pac J Cancer Prev, 15, 4629-35.   DOI
14 Usuda K, Sagawa M, Motono N, et al (2013). Advantages of diffusion-weighted imaging over positron emission tomography-computed tomography in assessment of hilar and mediastinal lymph node in lung cancer. Ann Surg Oncol, 20, 1676-83.   DOI
15 Darge K, Jaramillo D, Siegel MJ (2008). Whole-body MRI in children: current status and future applications. Eur J Radiol, 68, 289-98.   DOI
16 Li B, Li Q, Nie W, et al (2014). Diagnostic value of wholebody diffusion-weighted magnetic resonance imaging for detection of primary and metastatic malignancies: a metaanalysis. Eur J Radiol, 83, 338-44.   DOI
17 Lin WY, Hsu WH, Lim Kh, et al (2012). Role of preoperative PET-CT in assessing mediastinal and hilar lymph node status in early stage lung cancer. J Chin Med Assoc, 75, 203-8.   DOI
18 Maturu VN, Agarwal R, Aggarwal AN, et al (2014). Dual-time point whole-body 18F-fluorodeoxyglucose PET/CT imaging in undiagnosed mediastinal lymphadenopathy: a prospective study of 117 patients with sarcoidosis and TB. Chest, 146, e216-20.   DOI
19 Abdulqadhr G, Molin D, Astrom G, et al (2011). Whole-body diffusion-weighted imaging compared with FDG-PET/CT in staging of lymphoma patients. Acta Radiol, 52, 173-80.   DOI
20 Cheran SK, Nielsen ND, Patz EFJr (2004). False-negative findings for primary lung tumors on FDG positron emission tomography. Staging and prognostic implications. AJR, 182, 1129-32.   DOI
21 Gong J, Cao W, Zhang Z, et al (2015). Diagnostic efficacy of whole-body diffusion-weighted imaging in the detection of tumour recurrence and metastasis by comparison with 18F-2-fluoro-2-deoxy-D-glucose positron emission tomography or computed tomography in patients with gastrointestinal cancer. Gastroenterol Rep, 3, 128-35.   DOI
22 Goo JM, Im JG, Do KH, et al (2000). Pulmonary tuberculoma evaluated by means of FDG PET. Findings in 10 cases. Radiol, 216, 117-21.   DOI
23 Heusner TA, Kuemmel S, Koeninger A, et al (2010). Diagnostic value of diffusion-weighted magnetic resonance imaging (DWI) compared to FDG PET/CT for whole-body breast cancer staging. Eur J Nucl Med Mol Imaging, 37, 1077-86.   DOI
24 Higashi K, Ueda Y, Seki H, et al (1998). Fluorine-18-FDG PET imaging is negative in bronchioloalveolar lung carcinoma. J Nucl Med, 39, 1016-20.
25 International Union Against Cancer (2009). TNM classification of malignant tumours. 7th ed. NY: Wiley-Liss, 138-46.
26 Jain V, Hasselquist S, Delaney MD (2011). PET scanning in sarcoidosis. Ann N Y Acad Sci, 1228, 46-58.   DOI
27 Usuda K, Zhao XT, Sagawa M, et al (2011). Diffusion-weighted imaging is superior to PET in the detection and nodal assessment of lung cancers. Ann Thorac Surg, 91, 1689-95.   DOI
28 Michielsen K, Vergote I, Op de Beeck K, et al (2014). Wholebody MRI with diffusion-weighted sequence for staging of patients with suspected ovarian cancer: a clinical feasibility study in comparison to CT and FDG-PET/CT. Eur Radiol, 24, 889-901.   DOI
29 Nomori H, Mori T, Ikeda K, et al (2008). Diffusion-weighted magnetic resonance imaging can be used in place of positron emission tomography for N staging of non-small cell lung cancer with fewer false-positive results. J Thoracic Cardiovasc Surg, 135, 816-22.   DOI
30 Nomori H, Watanabe K, Ohtsuka T, et al (2004). Evaluation of F-18 fluorodeoxyglucose (FDG) PET scanning for pulmonary nodules less than 3cm in diameter, with special reference to the CT images. Lung Cancer, 45, 19-27.   DOI
31 van Ufford HME, Kwee TC, Beek FJ, et al (2011). Newly diagnosed lymphoma: initial results with whole-body T1-weighted, STIR, and diffusion-weighted MRI compared with $^{18}F$-FDG PET/CT. AJR Am J Roentgenol, 196, 662-9.   DOI
32 Xue HD, Li S, Sun HY, et al (2008). Experimental study of inflammatory and metastatic lymph nodes with diffusion weighted imaging on animal model: comparison with conventional methods. Chin Med Sci J, 23, 166-71.   DOI
33 Schmidt GP, Kramer H, Reiser MF, et al (2007). Wholebody magnetic resonance imaging and positron emission tomography-computed tomography in oncology. Top Magn Reson Imaging, 18, 193-202.   DOI
34 Ohno Y, Koyama H, Onishi Y, et al (2008). Non-small cell lung cancer: whole-body MR examination for M-stage assessment - utility for whole-body diffusion-weighted imaging compared with integrated FDG PET/CT. Radiol, 248, 643-54.   DOI
35 Plathow C, Aschoff P, Lichy MP, et al (2008). Positron emission tomography/computed tomography and wholebody magnetic resonance imaging in staging of advanced nonsmall cell lung cancer--initial results. Invest Radiol, 43, 290-7.   DOI
36 Schmidt GP, Baur-Melnyk A, Herzog P, et al (2005). Highresolution whole-body magnetic resonance image tumor staging with the use of parallel imaging versus dual-modality positron emission tomography-computed tomography: experience on a 32-channel system. Invest Radiol, 40, 743-53.   DOI
37 Schmidt GP, Reiser MF, Baur-Melnyk A (2009). Wholebody MRI for the staging and follow-up of patients with metastasis. Eur J Radiol, 70, 393-400.   DOI